The Surgical Research Society Annual Meeting will be held virtually on the 24th and 25th March 2021.
Abstracts have been received and we are delighted with the quality of same and look forward to hearing all the presentations.
We are delighted to be joined by Dr. Muriel Brackstone a surgical oncologist in London, Canada and Professor of Surgery and Oncology at the University of Western Ontario who will be delivering the BJS Lecture and Professor Mike Murphy, Professor of Mitochondrial Redox Biology at the University of Cambridge who is delivering the John Farndon Memorial Lecture.
We are delighted to again be hosting the RCS(Eng) Research Fellows session and will be joined by ASiT for a workshop on Innovations in Training. Winning presenters from the International Surgical Research Societies in Europe, South Africa and America will also be joining us.
We have a very exciting programme and we do hope you will join us for the event. Registration is free and can be accessed using the link below. Registration closing date is 10th March 2021.
Wednesday 24th March 2021
- 16.00 – John Farndon Lecture: Professor Michael Murphy
- 16.30 – RCS(Eng) Fellows Symposium
- 18.00 – Cohort Studies Presentations
- 18.00 – Basic Sciences Presentations
- 19.00 – Patey Prize Session
Thursday 25th March 2021
- 16.00 – COVID Presentations
- 17.00 – Systematic Review/Meta Analysis Presentations
- 17.00 – Education and Training Presentations
- 17.45 – Experimental & Database Presentations
- 17.45 – ASiT Innovations in Training Session
- 18.45 – Patey Prize Session
- 19.45 – BJS Lecture: Dr. Muriel Brackstone
- 20.15 – Presentation of Prizes
Dr. Brackstone Bio
She obtained her Medical Degree and General Surgical Residency at the University of Western Ontario and her fellowship in Breast Surgical Oncology at the University of Toronto. As a practicing surgeon, she obtained her Masters Degree in Epidemiology & Biostatistics followed by a PhD in Clinical Trials (Dept Pathology).
She is the Medical Director of London’s Breast Care Program and founding Director of the London Tumour Biobank, which is a biospecimen repository and translational research platform for serial imaging, tumour biopsies and blood collection with life-long clinical follow-up data. She is the lead author of national guidelines for the management of locally advanced breast cancer and management of the axilla. She co-founded Canada’s only hands-on Oncoplastic Surgery Training Program and has developed the standards for the role of oncoplastic surgery in breast conservation in Canada.
She has conducted a number of clinical trials most notably in the neoadjuvant setting, including the role of concurrent neoadjuvant radiation with chemotherapy in breast cancer, the role of probiotics on the inflammation-inducing breast microbiome, hypofractionated radiation in the neoadjuvant setting and its role in immune priming, with an ongoing research program in prone hypofractionated radiation concurrent with immune checkpoint inhibitors. She has over 100 peer reviewed publications with 50 peer reviewed grants to date. Dr. Brackstone is also a practicing general surgeon with four young children.
Professor Mike Murphy Bio
Mike Murphy received his BA in chemistry at Trinity College, Dublin in 1984 and his PhD in Biochemistry at Cambridge University in 1987. After stints in the USA, Zimbabwe, and Ireland he took up a faculty position in the Biochemistry Department at the University of Otago, Dunedin, New Zealand in 1992. In 2001 he moved to the MRC Mitochondrial Biology Unit in Cambridge, UK (then called the MRC Dunn Human Nutrition Unit) where he is a programme leader.
Murphy’s research focuses on the roles of reactive oxygen species in mitochondrial function and pathology. In particular he has pioneered the targeting of bioactive and probe molecules to mitochondria in vivo. This general methodology is now widely used. Prominent mitochondria-targeted compounds are antioxidants, such as MitoQ, which protects against oxidative damage in ischaemia-reperfusion injury. Murphy and Rob Smith developed MitoQ as an oral drug which has been used in two Phase II trials so far. This work established mitochondria as a relevant drug target and opened up the field of mitochondrial pharmacology. The Murphy group has gone on to create MitoSNO, a mitochondria-targeted nitric oxide donor which is now being developed as a potential therapy for cardiac ischaemia-reperfusion injury, and MitoG to treat diabetes.
Recently his work has extended to determining the mechanism by which mitochondria produce free radicals during ischaemia-reperfusion injury in heart attack and stroke. Murphy is Professor of Mitochondrial Redox Biology at the University of Cambridge, a Wellcome Trust Investigator, honorary research Professor at the University of Otago, New Zealand, a recipient of the Keilin Medal from the Biochemical Society, an honorary Fellow of the Royal Society of New Zealand and a Fellow of the Academy of Medical Sciences (FMedSci). He has published more than 345 peer reviewed papers, which have garnered more than 39,000 citations and he has an h-index of 106.